Received Jul 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 2 | 946889 | IM |
The patient did not report any adverse effects, however, we needed to report that the patient received this dose 27 days after the previous dose instead of the minimum interval of 28 days. The patient is also aware.